MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
2.35%
Quick Ratio
2.35%
Cash Ratio
0.69%
Debt to Asset Ratio
6.22%
Unit: Dollar
Assets Breakdown
    • Cash and investments held in tru...
    • Prepaid expenses and other curre...
    • Cash
Liabilities Breakdown
    • Ordinary shares subject to possi...
    • Accumulated deficit
    • Deferred underwriting fee payabl...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash
20,280
14,887
6,137
717
Prepaid expenses and other current assets
48,904
-
6,054
27,479
Total current assets
69,184
14,887
12,191
28,196
Cash and investments held in trust account
146,834,251
242,020,416
239,906,656
237,604,232
Total non-current assets
146,834,251
242,020,416
239,906,656
-
Total assets
146,903,435
242,035,303
239,918,847
237,632,428
Accounts payable and accrued expenses
254,412
238,181
222,184
-
Accrued offering costs
78,988
153,988
-
-
Extension advance note
-600,000
-
-
-
Accounts payable and accrued expenses
-
-
-
302,623
Interim note
350,000
100,000
-
-
Accrued offering costs
-
-
153,988
153,988
Share redemptions payable
1,661,224
-
-
-
Total current liabilities
2,944,624
492,169
376,172
456,611
Deferred underwriting fee payable
6,192,000
6,900,000
6,900,000
6,900,000
Total non-current liabilities
6,192,000
6,900,000
6,900,000
-
Total liabilities
9,136,624
7,392,169
7,276,172
7,356,611
Ordinary shares subject to possible redemption, 13,559,770 and 23,000,000 shares as of june 30, 2026 and december 31, 2025, respectively, at redemption value of 10.71 and 10.43 per share, respectively
145,173,027
242,020,416
239,906,656
237,604,232
Ordinary shares, 0.0001 par value 220,000,000 shares authorized 10,717,143 shares issued and outstanding, excluding 13,559,770 and 23,000,000 shares subject to redemption as of june 30, 2026 and december 31, 2025, respectively
1,072
1,072
1,072
1,052
Share subscription receivable
-
-
-
608,822
Accumulated deficit
-7,407,288
-7,378,354
-7,265,053
-6,720,645
Total shareholders deficit
-7,406,216
-7,377,282
-7,263,981
-7,328,415
Total liabilities, ordinary shares subject to possible redemption and shareholders deficit
146,903,435
242,035,303
239,918,847
237,632,428
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and investmentsheld in trust account$146,834,251 (-37.56%↓ Y/Y)Prepaid expenses andother current assets$48,904 (0.00%↑ Y/Y)Cash$20,280 (2367.15%↑ Y/Y)Total non-currentassets$146,834,251 Total current assets$69,184 (39.13%↑ Y/Y)Total assets$146,903,435 (-37.54%↓ Y/Y)Accumulated deficit-$7,407,288 (-14.72%↓ Y/Y)Total liabilities,ordinary shares subject...$146,903,435 (-37.54%↓ Y/Y)Total shareholdersdeficit-$7,406,216 (-3.56%↓ Y/Y)Ordinary shares, 0.0001par value...$1,072 (1.90%↑ Y/Y)Ordinary shares subjectto possible...$145,173,027 (-38.27%↓ Y/Y)Total liabilities$9,136,624 (26.87%↑ Y/Y)Total non-currentliabilities$6,192,000 Total currentliabilities$2,944,624 (876.85%↑ Y/Y)Deferred underwritingfee payable$6,192,000 (-10.26%↓ Y/Y)Share redemptionspayable$1,661,224 Extension advance note-$600,000 Interim note$350,000 Accounts payable andaccrued expenses$254,412 (72.54%↑ Y/Y)Accrued offering costs$78,988 (-48.71%↓ Y/Y)

Drugs Made In America Acquisition Corp. (DMAAU)

Drugs Made In America Acquisition Corp. (DMAAU)